Unima

Unima developed a fast and low-cost diagnostic and real-time disease surveillance that allows anyone to diagnose a disease directly where the patient is, without using lab equipment, with results in 15 minutes and at a very low cost.

High-Level Overview

Unima is a biotech company that develops fast, low-cost diagnostic tests and real-time disease surveillance technology aimed at enabling disease diagnosis directly at the point of care without the need for lab equipment. Their flagship platform, called *Find*, integrates biotechnology and artificial intelligence to create rapid diagnostic tests tailored to healthcare organizations, pharmaceutical companies, and public health systems. This platform not only delivers results in about 15 minutes but also uploads data in real time to the cloud, facilitating immediate analytics and outbreak tracking. Unima primarily serves emerging and developing countries, addressing the diagnostic challenges faced by over 3 billion people who lack timely access to medical testing. Their product portfolio includes rapid tests for tuberculosis, COVID-19, dengue, influenza, urinary tract infections, and agricultural diseases, with regulatory approvals and market launches in multiple countries[1][2][4].

Origin Story

Founded in 2015 in Zapopan, Mexico, Unima was created by a team including Jose Luis Nuno (Founder/CEO), Rodrigo Nuno (Founder and Director of Engineering), Maria Laura Mendoza (Founder/CPO), and Alejandro Nuño Ayala (Founder/R&D Director). The founders brought diverse expertise spanning manufacturing, engineering, quality control, and research and development. The idea emerged from the need to provide affordable, accessible diagnostics outside centralized labs, especially in resource-limited settings. Early traction included the transition from veterinary products to human diagnostics and securing product approvals for tuberculosis tests in Mexico and Indonesia, as well as a CE-marked COVID-19 saliva antigen test launched in Chile, Malaysia, and Germany[1][2].

Core Differentiators

• Product Differentiators: Unima’s *Find* platform combines biotechnology with AI to develop customizable rapid diagnostic tests that deliver results in 15 minutes without lab equipment.
• Real-Time Data Reporting: Test results are uploaded instantly to the cloud, enabling real-time disease surveillance and analytics for healthcare providers and public health authorities.
• Accessibility and Cost: Designed for use in remote and underserved areas, the tests are low-cost and easy to administer by non-specialists.
• Regulatory Approvals and Market Reach: Products have received regulatory clearance (e.g., CE Mark) and are deployed in multiple countries, demonstrating scalability and compliance.
• Versatility: The platform supports diagnostics across human infectious diseases and agricultural pathogens, broadening its impact scope[1][2][3].

Role in the Broader Tech Landscape

Unima operates at the intersection of biotechnology, artificial intelligence, and digital health, riding the global trend toward decentralized, point-of-care diagnostics and real-time health data analytics. The timing is critical given increasing demands for rapid outbreak detection, especially in the context of climate change-driven disease spread and the COVID-19 pandemic’s emphasis on accessible testing. Market forces favor solutions that reduce dependency on centralized labs, lower healthcare costs, and improve surveillance capabilities in vulnerable populations. By enabling real-time data sharing and analytics, Unima contributes to more agile public health responses and supports the global shift toward data-driven healthcare ecosystems[2][3].

Quick Take & Future Outlook

Looking ahead, Unima is well-positioned to expand its diagnostic portfolio and geographic footprint, leveraging its AI-powered platform to address emerging infectious diseases and agricultural health challenges. Trends such as digital health integration, AI-enhanced diagnostics, and global health security will shape its trajectory. Its influence may grow as governments and health organizations increasingly prioritize decentralized testing and real-time surveillance to manage pandemics and endemic diseases. Continued innovation and strategic partnerships will be key to scaling impact and maintaining competitive advantage in the evolving biotech landscape[2][4].

Unima’s mission to democratize access to diagnostics and real-time disease data ties back to its founding vision of empowering healthcare delivery where it is most needed, making it a critical player in the future of global health technology.